According to documents submitted to the U.S. Securities and Exchange Commission (SEC), Alto Neuroscience Inc (ANRO) is planning to accelerate and expand the clinical development of its candidate drug Alto-207 by adding a new phase III clinical trial.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
This initiative aims to further evaluate the efficacy and safety of the drug for the target indication, marking an important strategic step for the company in advancing its core pipeline. The new trial is expected to enrich the clinical data package, laying the foundation for subsequent regulatory communications and potential commercialization.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Crypto prices
More
Bitcoin
BTC
$62,592
-2.22%
Ethereum
ETH
$1,769.35
-1.99%
Tether USDt
USDT
$0.9992
-0.01%
USDC
USDC
$0.9999
+0.00%
XRP
XRP
$1.07
-2.40%
Solana
SOL
$75.8
-1.72%
TRON
TRX
$0.3266
-1.50%
Hyperliquid
HYPE
$64.33
-3.66%
Dogecoin
DOGE
$0.07204
-1.77%
Zcash
ZEC
$511.08
-2.33%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now